The DOI matches its Crossref record; 147 of the 147 references it cites were found in a registry or an index.
Peroxisome Proliferator-Activated Receptor-γ–Mediated Effects in the Vasculature
Open accessAbstract
Peroxisome proliferator-activated receptor (PPAR)-γ is a nuclear receptor and transcription factor in the steroid superfamily. PPAR-γ agonists, the thiazolidinediones, are clinically used to treat type 2 diabetes. In addition to its function in adipogenesis and increasing insulin sensitivity, PPAR-γ also plays critical roles in the vasculature. In vascular endothelial cells, PPAR-γ activation inhibits endothelial inflammation by suppressing inflammatory gene expression and therefore improves endothelial dysfunction. In vascular smooth muscle cells, PPAR-γ activation inhibits proliferation and migration and promotes apoptosis. In macrophages, PPAR-γ activation suppresses inflammation by regulating gene expression and increases cholesterol uptake and efflux. A recurring theme in many cell types is the modulation of the innate immunity system particularly through altering the activity of the nuclear factor κB. This system is likely to be even more prominent in modulating disease in vascular cells. The effects of PPAR-γ in the vascular cells translate into the beneficial function of this transcription factor in vascular disorders, including hypertension and atherosclerosis. Both human genetic studies and animal studies using transgenic mice have demonstrated the importance of PPAR-γ in these disorders. However, recent clinical studies have raised significant concerns about the cardiovascular side effects of thiazolidinediones, particularly rosiglitazone. Weighing the potential benefit and harm of PPAR-γ activation and exploring the functional mechanisms may provide a balanced view on the clinical use of these compounds and new approaches to the future therapeutics of vascular disorders associated with diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atherosclerosis--an inflammatory disease
Ross, R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400207 · Cited by 21,725
The pathogenesis of atherosclerosis: a perspective for the 1990s
Ross, R. (1993) · Nature · doi:10.1038/362801a0 · Cited by 10,630
Inflammation in atherosclerosis
Libby, P. (2002) · Nature · doi:10.1038/nature01323 · Cited by 8,315
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., & Kliewer, S. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.12953 · Cited by 3,625
The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
Peroxisome Proliferator-Activated Receptors: Nuclear Control of Metabolism*
Desvergne, B., & Wahli, W. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.5.0380 · Cited by 3,086
Glass, C. K., & Witztum, J. L. (2001) · Cell · doi:10.1016/s0092-8674(01)00238-0 · Cited by 3,051
PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
Jiang, C., Ting, A. T., & Seed, B. (1998) · Nature · doi:10.1038/34184 · Cited by 2,899
15-Deoxy-Δ12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ
Forman, B. M., Tontonoz, P., Chen, J., Brun, R. P., Spiegelman, B. M., & Evans, R. M. (1995) · Cell · doi:10.1016/0092-8674(95)90193-0 · Cited by 2,858
Cellular mechanisms of insulin resistance
Shulman, G. I. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10583 · Cited by 2,714
G1 phase progression: Cycling on cue
Sherr, C. J. (1994) · Cell · doi:10.1016/0092-8674(94)90540-1 · Cited by 2,674
Macrophage-specific PPARγ controls alternative activation and improves insulin resistance
Odegaard, J. I., Ricardo-Gonzalez, R. R., Goforth, M. H., Morel, C. R., Subramanian, V., Mukundan, L., Eagle, A. R., Vats, D., Brombacher, F., Ferrante, A. W., et al. (2007) · Nature · doi:10.1038/nature05894 · Cited by 2,107
Roles of PPARs in health and disease
Kersten, S., Desvergne, B., & Wahli, W. (2000) · Nature · doi:10.1038/35013000 · Cited by 1,956
Oxidized LDL Regulates Macrophage Gene Expression through Ligand Activation of PPARγ
Nagy, L., Tontonoz, P., Alvarez, J. G. A., Chen, H., & Evans, R. M. (1998) · Cell · doi:10.1016/s0092-8674(00)81574-3 · Cited by 1,860
Collins, T., Read, M. A., Neish, A. S., Whitley, M. Z., Thanos, D., & Maniatis, T. (1995) · The FASEB Journal · doi:10.1096/fasebj.9.10.7542214 · Cited by 1,718
Hyperinsulinemia as an independent risk factor for ischemic heart disease
Després, J.-P., Lamarche, B., Mauriège, P., Cantin, B., Dagenais, G. R., Moorjani, S., & Lupien, P.-J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199604113341504 · Cited by 1,699
PPARs and the complex journey to obesity
Evans, R. M., Barish, G. D., & Wang, Y.-X. (2004) · Nature Medicine · doi:10.1038/nm1025 · Cited by 1,602
Lehrke, M., & Lazar, M. A. (2005) · Cell · doi:10.1016/j.cell.2005.11.026 · Cited by 1,443
New functional activities for the p21 family of CDK inhibitors.
LaBaer, J., Garrett, M. D., Stevenson, L. F., Slingerland, J. M., Sandhu, C., Chou, H. S., Fattaey, A., & Harlow, E. (1997) · Genes & Development · doi:10.1101/gad.11.7.847 · Cited by 1,402
Barroso, I., Gurnell, M., Crowley, V. E. F., Agostini, M., Schwabe, J. W., Soos, M. A., Maslen, G. L., Williams, T. D. M., Lewis, H., Schafer, A. J., et al. (1999) · Nature · doi:10.1038/47254 · Cited by 1,368
A PPARγ-LXR-ABCA1 Pathway in Macrophages Is Involved in Cholesterol Efflux and Atherogenesis
Chawla, A., Boisvert, W. A., Lee, C.-H., Laffitte, B. A., Barak, Y., Joseph, S. B., Liao, D., Nagy, L., Edwards, P. A., Curtiss, L. K., et al. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00164-2 · Cited by 1,347
Diabetes, Hypertension, and Cardiovascular Disease: An Update
Sowers, J. R., Epstein, M., & Frohlich, E. D. (2001) · Hypertension · doi:10.1161/01.hyp.37.4.1053 · Cited by 1,332
Bouhlel, M. A., Derudas, B., Rigamonti, E., Dièvart, R., Brozek, J., Haulon, S., Zawadzki, C., Jude, B., Torpier, G., Marx, N., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.06.010 · Cited by 1,325
Boden, G., & Shulman, G. I. (2002) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.32.s3.3.x · Cited by 1,300
A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γ
Pascual, G., Fong, A. L., Ogawa, S., Gamliel, A., Li, A. C., Perissi, V., Rose, D. W., Willson, T. M., Rosenfeld, M. G., & Glass, C. K. (2005) · Nature · doi:10.1038/nature03988 · Cited by 1,254
Hypertension and Antihypertensive Therapy as Risk Factors for Type 2 Diabetes Mellitus
Gress, T. W., Nieto, F. J., Shahar, E., Wofford, M. R., & Brancati, F. L. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003303421301 · Cited by 1,202
PPARγ: a Nuclear Regulator of Metabolism, Differentiation, and Cell Growth
Rosen, E. D., & Spiegelman, B. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.r100034200 · Cited by 1,175
Chawla, A., Barak, Y., Nagy, L., Liao, D., Tontonoz, P., & Evans, R. M. (2001) · Nature Medicine · doi:10.1038/83336 · Cited by 1,069
Chinetti, G., Fruchart, J.-C., & Staels, B. (2000) · Inflammation Research · doi:10.1007/s000110050622 · Cited by 954
Minireview: Lipid Metabolism, Metabolic Diseases, and Peroxisome Proliferator-Activated Receptors
Lee, C.-H., Olson, P., & Evans, R. M. (2003) · Endocrinology · doi:10.1210/en.2003-0288 · Cited by 890
Interleukin-4-dependent production of PPAR-γ ligands in macrophages by 12/15-lipoxygenase
Huang, J. T., Welch, J. S., Ricote, M., Binder, C. J., Willson, T. M., Kelly, C., Witztum, J. L., Funk, C. D., Conrad, D., & Glass, C. K. (1999) · Nature · doi:10.1038/22572 · Cited by 855
Li, A. C., Brown, K. K., Silvestre, M. J., Willson, T. M., Palinski, W., & Glass, C. K. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10370 · Cited by 833
Nesto, R. W., Bell, D., Bonow, R. O., Fonseca, V., Grundy, S. M., Horton, E. S., Le Winter, M., Porte, D., Semenkovich, C. F., Smith, S., et al. (2003) · Circulation · doi:10.1161/01.cir.0000103683.99399.7e · Cited by 829
Goldberg, R. B., Kendall, D. M., Deeg, M. A., Buse, J. B., Zagar, A. J., Pinaire, J. A., Tan, M. H., Khan, M. A., Perez, A. T., Jacober, S. J., et al. (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1547 · Cited by 795
Rosiglitazone Evaluated for Cardiovascular Outcomes — An Interim Analysis
Home, P. D., Pocock, S. J., Beck-Nielsen, H., Gomis, R., Hanefeld, M., Jones, N. P., Komajda, M., & McMurray, J. J. V. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073394 · Cited by 761
NF-κB activation as a pathological mechanism of septic shock and inflammation
Liu, S. F., & Malik, A. B. (2006) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00477.2005 · Cited by 761
Functional plasticity of macrophages: reversible adaptation to changing microenvironments
Stout, R. D., & Suttles, J. (2004) · Journal of Leukocyte Biology · doi:10.1189/jlb.0504272 · Cited by 751
NF-κB: pivotal mediator or innocent bystander in atherogenesis?
Collins, T., & Cybulsky, M. I. (2001) · Journal of Clinical Investigation · doi:10.1172/jci10373 · Cited by 727
Ricote, M., Huang, J., Fajas, L., Li, A., Welch, J., Najib, J., Witztum, J. L., Auwerx, J., Palinski, W., & Glass, C. K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7614 · Cited by 721
PPARs: therapeutic targets for metabolic disease
Berger, J. P., Akiyama, T. E., & Meinke, P. T. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.03.003 · Cited by 713
Adiponectin: action, regulation and association to insulin sensitivity
Lihn, A. S., Pedersen, S. B., & Richelsen, B. (2005) · Obesity Reviews · doi:10.1111/j.1467-789x.2005.00159.x · Cited by 660
Molecular determinants of crosstalk between nuclear receptors and toll-like receptors
Ogawa, S., Lozach, J., Benner, C., Pascual, G., Tangirala, R. K., Westin, S., Hoffmann, A., Subramaniam, S., David, M., Rosenfeld, M. G., et al. (2005) · Cell · doi:10.1016/j.cell.2005.06.029 · Cited by 647
Galis, Z. S., Muszynski, M., Sukhova, G. K., Simon-Morrissey, E., Unemori, E. N., Lark, M. W., Amento, E., & Libby, P. (1994) · Circulation Research · doi:10.1161/01.res.75.1.181 · Cited by 646
Hypoadiponectinemia Is an Independent Risk Factor for Hypertension
Iwashima, Y., Katsuya, T., Ishikawa, K., Ouchi, N., Ohishi, M., Sugimoto, K., Fu, Y., Motone, M., Yamamoto, K., Matsuo, A., et al. (2004) · Hypertension · doi:10.1161/01.hyp.0000129281.03801.4b · Cited by 613
Guan, Y., Hao, C., Cha, D. R., Rao, R., Lu, W., Kohan, D. E., Magnuson, M. A., Redha, R., Zhang, Y., & Breyer, M. D. (2005) · Nature Medicine · doi:10.1038/nm1278 · Cited by 608
Marx, N., Schönbeck, U., Lazar, M. A., Libby, P., & Plutzky, J. (1998) · Circulation Research · doi:10.1161/01.res.83.11.1097 · Cited by 587
Peroxisome Proliferator–Activated Receptor γ and Metabolic Disease
Willson, T. M., Lambert, M. H., & Kliewer, S. A. (2001) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.70.1.341 · Cited by 582
PPARs and molecular mechanisms of transrepression
Ricote, M., & Glass, C. K. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.02.013 · Cited by 570
Macrophages in Human Atheroma Contain PPARγ
Marx, N., Sukhova, G., Murphy, C., Libby, P., & Plutzky, J. (1998) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65540-x · Cited by 529
Brasier, A. R. (2006) · Cardiovascular Toxicology · doi:10.1385/ct:6:2:111 · Cited by 528
The role of PPAR-γ in macrophage differentiation and cholesterol uptake
Moore, K. J., Rosen, E. D., Fitzgerald, M. L., Randow, F., Andersson, L. P., Altshuler, D., Milstone, D. S., Mortensen, R. M., Spiegelman, B. M., & Freeman, M. W. (2001) · Nature Medicine · doi:10.1038/83328 · Cited by 513
Self-citationXin, X., Yang, S., Kowalski, J., & Gerritsen, M. E. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.13.9116 · Cited by 513
Pasceri, V., Wu, H. D., Willerson, J. T., & Yeh, E. T. H. (2000) · Circulation · doi:10.1161/01.cir.101.3.235 · Cited by 504
Delerive, P., Martin-Nizard, F., Chinetti, G., Trottein, F., Fruchart, J.-C., Najib, J., Duriez, P., & Staels, B. (1999) · Circulation Research · doi:10.1161/01.res.85.5.394 · Cited by 502
The role of vascular smooth muscle cells on the pathogenesis of atherosclerosis.
Rudijanto, A. (2007) · PubMed · Cited by 495
Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia.
Law, R. E., Meehan, W. P., Xi, X. P., Graf, K., Wuthrich, D. A., Coats, W., Faxon, D., & Hsueh, W. A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118991 · Cited by 476
Potent Inhibitory Effect of Troglitazone on Carotid Arterial Wall Thickness in Type 2 Diabetes
Minamikawa, J. (1998) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.5.1818 · Cited by 461
Hevener, A. L., Olefsky, J. M., Reichart, D., Nguyen, M. T. A., Bandyopadyhay, G., Leung, H.-Y., Watt, M. J., Benner, C., Febbraio, M. A., Nguyen, A.-K., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31561 · Cited by 459
Peroxisome proliferator-activated receptor γ in diabetes and metabolism
Rangwala, S. M., & Lazar, M. A. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.03.012 · Cited by 450
Expression and Function of PPARγ in Rat and Human Vascular Smooth Muscle Cells
Law, R. E., Goetze, S., Xi, X.-P., Jackson, S., Kawano, Y., Demer, L., Fishbein, M. C., Meehan, W. P., & Hsueh, W. A. (2000) · Circulation · doi:10.1161/01.cir.101.11.1311 · Cited by 442
Savage, D. B., Tan, G. D., Acerini, C. L., Jebb, S. A., Agostini, M., Gurnell, M., Williams, R. L., Umpleby, A. M., Thomas, E. L., Bell, J. D., et al. (2003) · Diabetes · doi:10.2337/diabetes.52.4.910 · Cited by 430
Welch, J. S., Ricote, M., Akiyama, T. E., Gonzalez, F. J., & Glass, C. K. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1031789100 · Cited by 429
Nitrolinoleic acid. An endogenous peroxisome proliferator-activated receptor γ ligand
Schopfer, F. J., Lin, Y., Baker, P. R. S., Cui, T., Garcia-Barrio, M., Zhang, J., Chen, K., Chen, Y. E., & Freeman, B. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408384102 · Cited by 428
The Transcription Factor NF-κB and the Regulation of Vascular Cell Function
de Martin, R., Hoeth, M., Hofer-Warbinek, R., & Schmid, J. A. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.11.e83 · Cited by 408
SGalis, Z., MMuszynski, KSukhova, G., ESimon-Morrissey, NUnemori, E., WLark, M., EAmento, & PLibby (1994) · Circulation Research · Cited by 402
Collins, A. R., Meehan, W. P., Kintscher, U., Jackson, S., Wakino, S., Noh, G., Palinski, W., Hsueh, W. A., & Law, R. E. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.21.3.365 · Cited by 385
Jackson, S. M., Parhami, F., Xi, X.-P., Berliner, J. A., Hsueh, W. A., Law, R. E., & Demer, L. L. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.9.2094 · Cited by 373
Akiyama, T. E., Sakai, S., Lambert, G., Nicol, C. J., Matsusue, K., Pimprale, S., Lee, Y.-H., Ricote, M., Glass, C. K., Brewer, H. B., et al. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.8.2607-2619.2002 · Cited by 368
Peroxisome proliferator‐activated receptors in the cardiovascular system
Bishop‐Bailey, D. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703149 · Cited by 363
Marx, N., Bourcier, T., Sukhova, G. K., Libby, P., & Plutzky, J. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.3.546 · Cited by 362
Diep, Q. N., El Mabrouk, M., Cohn, J. S., Endemann, D., Amiri, F., Virdis, A., Neves, M. F., & Schiffrin, E. L. (2002) · Circulation · doi:10.1161/01.cir.0000016049.86468.23 · Cited by 345
Chen, Z., Ishibashi, S., Perrey, S., Osuga, J.-I., Gotoda, T., Kitamine, T., Tamura, Y., Okazaki, H., Yahagi, N., Iizuka, Y., et al. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.21.3.372 · Cited by 320
Zhang, H., Zhang, A., Kohan, D. E., Nelson, R. D., Gonzalez, F. J., & Yang, T. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501744102 · Cited by 317
Marx, N., Mach, F., Sauty, A., Leung, J. H., Sarafi, M. N., Ransohoff, R. M., Libby, P., Plutzky, J., & Luster, A. D. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.12.6503 · Cited by 296
Metabolic and Additional Vascular Effects of Thiazolidinediones
Martens, F. M. A. C., Visseren, F. L. J., Lemay, J., de Koning, E. J. P., & Rabelink, T. J. (2002) · Drugs · doi:10.2165/00003495-200262100-00004 · Cited by 291
Angiotensin II is associated with activation of NF-κB-mediated genes and downregulation of PPARs
Tham, D. M., Martin-McNulty, B., Wang, Y.-X., Wilson, D. W., Vergona, R., Sullivan, M. E., Dole, W., & Rutledge, J. C. (2002) · Physiological Genomics · doi:10.1152/physiolgenomics.00062.2002 · Cited by 277
Hwang, J., Kleinhenz, D. J., Lassègue, B., Griendling, K. K., Dikalov, S., & Hart, C. M. (2005) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00474.2004 · Cited by 268
Agarwal, A. K., & Garg, A. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.1.8290 · Cited by 268
PPARG F388L, a Transactivation-Deficient Mutant, in Familial Partial Lipodystrophy
Hegele, R. A., Cao, H., Frankowski, C., Mathews, S. T., & Leff, T. (2002) · Diabetes · doi:10.2337/diabetes.51.12.3586 · Cited by 264
A Novel Pathway to the Manifestations of Metabolic Syndrome
Sonnenberg, G. E., Krakower, G. R., & Kissebah, A. H. (2004) · Obesity Research · doi:10.1038/oby.2004.24 · Cited by 257
Cross-talk between nuclear receptors and nuclear factor κB
De Bosscher, K., Vanden Berghe, W., & Haegeman, G. (2006) · Oncogene · doi:10.1038/sj.onc.1209935 · Cited by 247
Strengths and limitations of meta-analysis: Larger studies may be more reliable
Flather, M. D., Farkouh, M. E., Pogue, J. M., & Yusuf, S. (1997) · Controlled Clinical Trials · doi:10.1016/s0197-2456(97)00024-x · Cited by 234
Wang, N., Verna, L., Chen, N.-G., Chen, J., Li, H., Forman, B. M., & Stemerman, M. B. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203436200 · Cited by 208
Endothelial dysfunction in insulin resistance and type 2 diabetes
Jansson, P. ‐. (2007) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2007.01830.x · Cited by 205
Wakino, S., Kintscher, U., Kim, S., Yin, F., Hsueh, W. A., & Law, R. E. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m910452199 · Cited by 201
Peroxisome proliferator-activated receptor-gamma ligands inhibit choroidal neovascularization.
Murata, T., He, S., Hangai, M., Ishibashi, T., Xi, X. P., Kim, S., Hsueh, W. A., Ryan, S. J., Law, R. E., & Hinton, D. R. (2000) · PubMed · Cited by 196
PPARγ and Atherosclerosis: Effects on Cell Growth and Movement
Hsueh, W. A., & Law, R. E. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/hq1201.100261 · Cited by 191
Goetze, S., Xi, X.-P., Kawano, H., Gotlibowski, T., Fleck, E., Hsueh, W. A., & Law, R. E. (1999) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199905000-00018 · Cited by 187
Ryan, M. J., Didion, S. P., Mathur, S., Faraci, F. M., & Sigmund, C. D. (2004) · Hypertension · doi:10.1161/01.hyp.0000116303.71408.c2 · Cited by 184
Satoh, H., Tsukamoto, K., Hashimoto, Y., Hashimoto, N., Togo, M., Hara, M., Maekawa, H., Isoo, N., Kimura, S., & Watanabe, T. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.0126 · Cited by 182
Babaev, V. R., Yancey, P. G., Ryzhov, S. V., Kon, V., Breyer, M. D., Magnuson, M. A., Fazio, S., & Linton, M. F. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000173413.31789.1a · Cited by 178
Rosiglitazone and Cardiovascular Risk
Psaty, B. M., & Furberg, C. D. (2007) · New England Journal of Medicine · doi:10.1056/nejme078099 · Cited by 178
Duan, S. Z., Ivashchenko, C. Y., Whitesall, S. E., D’Alecy, L. G., Duquaine, D. C., Brosius, F. C., Gonzalez, F. J., Vinson, C., Pierre, M. A., Milstone, D. S., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci28859 · Cited by 172
Self-citationPolikandriotis, J. A., Mazzella, L. J., Rupnow, H. L., & Hart, C. M. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000177805.65864.d4 · Cited by 169
The role of inflammation in vascular injury and repair
Davis, C., Fischer, J., Ley, K., & Sarembock, I. J. (2003) · Journal of Thrombosis and Haemostasis · doi:10.1046/j.1538-7836.2003.00292.x · Cited by 166
Hypertension and abnormal fat distribution but not insulin resistance in mice with P465L PPARγ
Tsai, Y.-S., Kim, H.-J., Takahashi, N., Kim, H.-S., Hagaman, J. R., Kim, J. K., & Maeda, N. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420964 · Cited by 158
Endothelial injury in the initiation and progression of vascular disorders
Tesfamariam, B., & DeFelice, A. (2006) · Vascular Pharmacology · doi:10.1016/j.vph.2006.11.005 · Cited by 151
Peroxisome proliferator-activated receptor γ C161→T polymorphism and coronary artery disease
Wang, X., Oosterhof, J., & Duarte, N. (1999) · Cardiovascular Research · doi:10.1016/s0008-6363(99)00256-4 · Cited by 136
Takata, Y., Kitami, Y., Yang, Z., Nakamura, M., Okura, T., & Hiwada, K. (2002) · Circulation Research · doi:10.1161/01.res.0000031271.20771.4f · Cited by 135
Mehta, J. L., Hu, B., Chen, J., & Li, D. (2003) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000094411.98127.5f · Cited by 134
Calkin, A. C., Forbes, J. M., Smith, C. M., Lassila, M., Cooper, M. E., Jandeleit-Dahm, K. A. M., & Allen, T. J. (2005) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000177813.99577.6b · Cited by 126
The Ubiquitin-Proteasome System and Inflammatory Activity in Diabetic Atherosclerotic Plaques
Marfella, R., D’Amico, M., Esposito, K., Baldi, A., Filippo, C. D., Siniscalchi, M., Sasso, F. C., Portoghese, M., Cirillo, F., Cacciapuoti, F., et al. (2006) · Diabetes · doi:10.2337/diabetes.55.03.06.db05-0832 · Cited by 125
Pioglitazone attenuates hypertension and inhibits growth of renal arteriolar smooth muscle in rats
Dubey, R. K., Zhang, H. Y., Reddy, S. R., Boegehold, M. A., & Kotchen, T. A. (1993) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1993.265.4.r726 · Cited by 119
Ginderachter, J. A. V., Meerschaut, S., Liu, Y., Brys, L., Groeve, K. D., Ghassabeh, G. H., Raes, G., & BAETSELIER, P. D. (2006) · Blood · doi:10.1182/blood-2005-09-3777 · Cited by 119
Verrier, E., Wang, L., Wadham, C., Albanese, N., Hahn, C. N., Gamble, J. R., Chatterjee, K., Vadas, M. A., & Xia, P. (2004) · Circulation Research · doi:10.1161/01.res.0000130527.92537.06 · Cited by 117
Troglitazone induces apoptosis via the p53 and Gadd45 pathway in vascular smooth muscle cells
Okura, T., Nakamura, M., Takata, Y., Watanabe, S., Kitami, Y., & Hiwada, K. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00758-5 · Cited by 107
PPAR? in endothelial cells influences high fat diet-induced hypertension
Nicol, C. J. B., ADACHI, M., AKIYAMA, T., & Gonzalez, F. J. (2005) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2004.10.032 · Cited by 105
IL‐13 induces expression of CD36 in human monocytes through PPARγ activation
Berry, A., Balard, P., Coste, A., Olagnier, D. P., Lagane, C., Authier, H., Benoit‐Vical, F., Lepert, J., Séguéla, J. P., Magnaval, J., et al. (2007) · European Journal of Immunology · doi:10.1002/eji.200636625 · Cited by 103
Bruemmer, D., Yin, F., Liu, J., Berger, J. P., Sakai, T., Blaschke, F., Fleck, E., Herle, A. J. V., FORMAN, B. M., & Law, R. E. (2003) · Circulation Research · doi:10.1161/01.res.0000088344.15288.e6 · Cited by 101
NF-κB in Cardiovascular Disease: Diverse and Specific Effects of a "General" Transcription Factor?
Jones, W. K., Brown, M. A., Wilhide, M. E., He, S., & Ren, X. (2005) · Cardiovascular Toxicology · doi:10.1385/ct:5:2:183 · Cited by 87
Role of PPARγ in macrophage biology and atherosclerosis
Zhang, L., & Chawla, A. (2004) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2004.10.006 · Cited by 82
Cell death in the cardiovascular system
Clarke, M. C. H., Bennett, M. R., & Littlewood, T. D. (2006) · Heart · doi:10.1136/hrt.2006.088203 · Cited by 81
Ogawa, D., Nomiyama, T., Nakamachi, T., Heywood, E. B., Stone, J. F., Berger, J. P., Law, R. E., & Bruemmer, D. (2006) · Circulation Research · doi:10.1161/01.res.0000218271.93076.c3 · Cited by 79
Free fatty acids and insulin secretion in humans
Boden, G. H. (2005) · Current Diabetes Reports · doi:10.1007/s11892-005-0004-5 · Cited by 79
Levi, Z., Shaish, A., Yacov, N., Levkovitz, H., Trestman, S., Gerber, Y., Cohen, H. W., Dvir, A., Rhachmani, R., Ravid, M., et al. (2003) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2003.00240.x · Cited by 78
Freedman, B. D., Lee, E. J., Park, Y., & Jameson, J. L. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m407539200 · Cited by 78
Wakino, S., Kintscher, U., Liu, Z., Kim, S., Yin, F., Ohba, M., Kuroki, T., Schönthal, A. H., Hsueh, W. A., & Law, R. E. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m108719200 · Cited by 77
PPAR-γ inhibits ANG II-induced cell growth via SHIP2 and 4E-BP1
Benkirane, K., Amiri, F., Diep, Q. N., Mabrouk, M. E., & Schiffrin, E. L. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00662.2005 · Cited by 70
Hyperglycaemia and cardiovascular disease
Bartnik, M., Norhammar, A., & Rydén, L. (2007) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2007.01831.x · Cited by 69
Ptasinska, A., Wang, S., Zhang, J., WESLEY, R. A., & Danner, R. L. (2006) · The FASEB Journal · doi:10.1096/fj.06-6822com · Cited by 69
Sasaki, M., Jordan, P., Welbourne, T., Minagar, A., Joh, T., Itoh, M., Elrod, J. W., & Alexander, J. S. (2005) · BMC Physiology · doi:10.1186/1472-6793-5-3 · Cited by 66
Goetze, S., Kintscher, U., Kim, S., Meehan, W. P., Kaneshiro, K., Collins, A. R., Fleck, E., Hsueh, W. A., & Law, R. E. (2001) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200112000-00013 · Cited by 64
stgren, C. J., Lindblad, U., Melander, O., Melander, A., Groop, L., & stam, L. R. (2003) · Journal of Hypertension · doi:10.1097/00004872-200309000-00014 · Cited by 60
Östgren, C. J., Lindblad, U., Melander, O., Melander, A., Groop, L., & Råstam, L. (2003) · PubMed · doi:10.1097/01.hjh.0000084734.53355.0d · Cited by 56
Kwak, B. R., Myit, S., Mulhaupt, F., Veillard, N. R., Rufer, N., Roosnek, E. E., & Mach, F. (2002) · Circulation Research · doi:10.1161/hh0302.104924 · Cited by 56
Lincoff, A. M., Wolski, K., Nicholls, S. J., & Nissen, S. E. (2007) · JAMA · doi:10.1001/jama.298.10.1180 · Cited by 52
Harte, A. L., McTernan, P. G., McTernan, C. L., Smith, S. A., Barnett, A. H., & Kumar, S. (2003) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2003.00276.x · Cited by 51
Metabolic syndrome-interdependence of the cardiovascular and metabolic pathways
Caglayan, E., Blaschke, F., Takata, Y., & Hsueh, W. A. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.01.008 · Cited by 50
Imamoto, E., Yoshida, N., Uchiyama, K., Kuroda, M., Kokura, S., Ichikawa, H., Naito, Y., Tanigawa, T., & Yoshikawa, T. (2004) · BioFactors · doi:10.1002/biof.5520200104 · Cited by 49
Sigrist, S., Bedoucha, M., & Boelsterli, U. A. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00299-9 · Cited by 49
Kim, K. Y., & Cheon, H. G. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m510357200 · Cited by 46
Gottschling-Zeller, H., Röhrig, K., & Hauner, H. (2000) · Diabetologia · doi:10.1007/s001250050057 · Cited by 41
Semple, R. K., Meirhaeghe, A., Vidal‐Puig, A., Schwabe, J. W. R., Wiggins, D., Gibbons, G. F., Gurnell, M., Chatterjee, K., & O’Rahilly, S. (2005) · Endocrinology · doi:10.1210/en.2004-1405 · Cited by 41
Rodríguez-Granillo, G. A., Agostoni, P., García‐García, H. M., Biondi‐Zoccai, G., Fadden, E. P. M., Amoroso, G., de Jaegere, P. P. T., Bruining, N., de Feyter, P. J., & Serruys, P. W. J. C. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.07.054 · Cited by 40
Interferon Regulatory Factor-1 Mediates PPARγ-Induced Apoptosis in Vascular Smooth Muscle Cells
Lin, Y., Zhu, X., Mclntee, F. L., Xiao, H., Zhang, J., Fu, M., & Chen, Y. E. (2003) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000109170.43400.2f · Cited by 38
Preventing Macrovascular Complications in Type 2 Diabetes Mellitus: Glucose Control and Beyond
Stancoven, A., & McGuire, D. K. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.04.005 · Cited by 37
Troglitazone inhibits mitogenic signaling by insulin in vascular smooth muscle cells.
Goetze, S., Kim, S., Xi, X., Graf, K., Yang, D., Fleck, E., Meehan, W. P., Hsueh, W. A., & Law, R. (2000) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200005000-00011 · Cited by 37
Vascular protection in diabetes: a pharmacological view of angiotensin II type 1 receptor blockers
Kintscher, U., & Unger, T. (2005) · Acta Diabetologica · doi:10.1007/s00592-005-0178-y · Cited by 34
Ruiz, E., Redondo, S., Gordillo‐Moscoso, A., & Tejerina, T. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.114934 · Cited by 31
Lu, G., Chiem, A. T., Anuurad, E., Havel, P. J., Pearson, T. A., Ormsby, B., & Berglund, L. (2007) · Translational research · doi:10.1016/j.trsl.2006.12.008 · Cited by 27
Can PPARγ agonists have a role in the management of obesity-related hypertension?
Chetty, V. T., & Sharma, A. M. (2006) · Vascular Pharmacology · doi:10.1016/j.vph.2005.11.010 · Cited by 27
Heo, K., Kim, D.-U., Ryoo, S., Nam, M., Baek, S. T., Kim, L., Park, S., Myung, C., & Hoe, K. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.06.006 · Cited by 18
Long-term Risk of Cardiovascular Events With Rosiglitazone: A Meta-analysis
Singh, S., Loke, Y. K., & Furberg, C. D. (2007) · JAMA · doi:10.1001/jama.298.10.1189 · Cited by 5
Cited by
Mechanisms of disease: pulmonary arterial hypertension
Schermuly, R. T., Ghofrani, H. A., Wilkins, M. R., & Grimminger, F. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.87 · Cited by 800
Role of the renin–angiotensin system in vascular inflammation
Marchesi, C., Paradis, P., & Schiffrin, E. L. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.05.003 · Cited by 432
Calcific Aortic Valve Stenosis: Methods, Models, and Mechanisms
Miller, J. D., Weiss, R. M., & Heistad, D. D. (2011) · Circulation Research · doi:10.1161/circresaha.110.234138 · Cited by 323
PPAR-γ signaling in nonalcoholic fatty liver disease: Pathogenesis and therapeutic targets
Chen, H., Tan, H., Wan, J., Zeng, Y., Wang, J., Wang, H., & Lu, X. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108391 · Cited by 311
Han, L., Shen, W.-J., Bittner, S., Kraemer, F. B., & Azhar, S. (2017) · Future Cardiology · doi:10.2217/fca-2017-0019 · Cited by 256
Metadata
- Authors
- Duan, S. Z., Usher, M. G., & Mortensen, R. M.
- Venue
- Circulation Research
- Published
- 2008-02-15
- Volume
- 102
- Issue
- 3
- Pages
- 283-294
- ISSN
- 0009-7330 (ISSN-L)
- 1524-4571
- OpenAlex
- W2098108405
- Cited by
- 263
- References
- 147
- FWCI
- 11.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.